Analyst Price Targets — SEPN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 1:24 pm | Josh Schimmer | Cantor Fitzgerald | $60.00 | $28.06 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Septerna Inc (SEPN) |
| January 20, 2026 11:19 am | — | H.C. Wainwright | $35.00 | $26.07 | TheFly | Septerna price target raised to $35 from $30 at H.C. Wainwright |
| December 19, 2025 11:28 am | Martin Auster | Raymond James | $38.00 | $27.54 | TheFly | Septerna initiated with a Strong Buy at Raymond James |
| December 15, 2025 11:08 am | — | Truist Financial | $34.00 | $25.47 | TheFly | Septerna initiated with a Buy at Truist |
| November 14, 2025 10:13 am | Derek Archila | Wells Fargo | $28.00 | $19.24 | TheFly | Septerna upgraded to Overweight from Equal Weight at Wells Fargo |
| May 16, 2025 10:15 am | Derek Archila | Wells Fargo | $18.00 | $9.84 | TheFly | Septerna price target raised to $18 from $11 at Wells Fargo |
| March 28, 2025 10:22 am | — | Wells Fargo | $11.00 | $6.10 | TheFly | Septerna price target lowered to $11 from $14 at Wells Fargo |
| February 18, 2025 1:30 pm | Derek Archila | Wells Fargo | $14.00 | $12.96 | TheFly | Wells Fargo downgrades Septerna after lead program SEP-786 discontinued |
Latest News for SEPN
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.64 per share a year ago.
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN),…
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing Phase 2 Development Planned to Begin with Chronic Spontaneous Urticaria in the Second Half of 2026…
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SEPN.
U.S. House Trading
No House trades found for SEPN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.